ShanXi C&Y Pharmaceutical GroupLTD Past Earnings Performance
Past criteria checks 2/6
ShanXi C&Y Pharmaceutical GroupLTD's earnings have been declining at an average annual rate of -5.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 7.9% per year. ShanXi C&Y Pharmaceutical GroupLTD's return on equity is 8.8%, and it has net margins of 5.7%.
Key information
-5.8%
Earnings growth rate
-4.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -7.9% |
| Return on equity | 8.8% |
| Net Margin | 5.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How ShanXi C&Y Pharmaceutical GroupLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 806 | 46 | 443 | 53 |
| 31 Dec 23 | 799 | 25 | 453 | 50 |
| 30 Sep 23 | 767 | -107 | 465 | 57 |
| 30 Jun 23 | 790 | -120 | 492 | 55 |
| 31 Mar 23 | 820 | -119 | 514 | 54 |
| 01 Jan 23 | 829 | -119 | 535 | 55 |
| 30 Sep 22 | 847 | -111 | 554 | 52 |
| 30 Jun 22 | 878 | -110 | 577 | 53 |
| 31 Mar 22 | 899 | -94 | 585 | 57 |
| 01 Jan 22 | 930 | -91 | 599 | 57 |
| 30 Sep 21 | 966 | -144 | 651 | 72 |
| 30 Jun 21 | 911 | -191 | 657 | 77 |
| 31 Mar 21 | 920 | -218 | 705 | 72 |
| 31 Dec 20 | 848 | -262 | 698 | 72 |
| 30 Sep 20 | 861 | -162 | 704 | 57 |
| 30 Jun 20 | 968 | -112 | 767 | 49 |
| 31 Mar 20 | 1,029 | -58 | 782 | 47 |
| 31 Dec 19 | 1,132 | 5 | 818 | 49 |
| 30 Sep 19 | 1,184 | 29 | 815 | 43 |
| 30 Jun 19 | 1,154 | 32 | 772 | 50 |
| 31 Mar 19 | 1,119 | 20 | 740 | 55 |
| 31 Dec 18 | 1,136 | 7 | 748 | 54 |
| 30 Sep 18 | 1,092 | 20 | 718 | 62 |
| 30 Jun 18 | 1,058 | 18 | 673 | 70 |
| 31 Mar 18 | 1,024 | 23 | 631 | 54 |
| 31 Dec 17 | 939 | 22 | 557 | 43 |
| 30 Sep 17 | 891 | 25 | 513 | 26 |
| 30 Jun 17 | 834 | 31 | 485 | 0 |
| 31 Mar 17 | 791 | 30 | 457 | 0 |
| 31 Dec 16 | 746 | 30 | 438 | 0 |
| 30 Sep 16 | 732 | 22 | 443 | 0 |
| 30 Jun 16 | 704 | 24 | 427 | 0 |
| 31 Mar 16 | 683 | 22 | 416 | 0 |
| 31 Dec 15 | 684 | 23 | 409 | 0 |
| 30 Sep 15 | 669 | 40 | 388 | 0 |
| 30 Jun 15 | 666 | 40 | 389 | 0 |
| 31 Mar 15 | 660 | 41 | 385 | 0 |
| 31 Dec 14 | 654 | 41 | 383 | 0 |
| 30 Sep 14 | 646 | 38 | 361 | 0 |
| 30 Jun 14 | 598 | 33 | 329 | 0 |
| 31 Mar 14 | 547 | 29 | 295 | 0 |
| 31 Dec 13 | 514 | 27 | 277 | 0 |
| 30 Sep 13 | 429 | 29 | 236 | 0 |
| 30 Jun 13 | 415 | 27 | 225 | 0 |
Quality Earnings: 300254 has a large one-off gain of CN¥37.1M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300254 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300254 has become profitable over the past 5 years, growing earnings by -5.8% per year.
Accelerating Growth: 300254 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300254 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.1%).
Return on Equity
High ROE: 300254's Return on Equity (8.8%) is considered low.